Antibiotic

Assessment of COVID-19's Effect on Sanitizer Market 2020-2024 | Evolving Opportunities with 3M Co. and Godrej Consumer Products Ltd. | Technavio

Thursday, July 2, 2020 - 7:00pm

In addition, the introduction of new products is anticipated to boost the growth of the sanitizer market.

Key Points: 
  • In addition, the introduction of new products is anticipated to boost the growth of the sanitizer market.
  • Hand sanitizer contains at least 60% of alcohol, which kills most kinds of bacteria, including antibiotic-resistant bacteria and tuberculosis bacteria.
  • Godrej Consumer Products Ltd. operates its business through segments such as India, Indonesia, Africa (Including Strength of Nature), and Others.
  • Sanitizer Market Product Outlook (Revenue, USD Billion, 2020-2024)
    Sanitizer Market Geography Outlook (Revenue, USD Billion, 2020-2024)

Assessment of North America's Antibiotics Market 2019-2027: Impact of COVID-19 on the $18+ Billion-Projected Industry - ResearchAndMarkets.com

Thursday, July 2, 2020 - 10:42am

The "North America Antibiotics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class; Action Mechanism; and Country" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Antibiotics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class; Action Mechanism; and Country" report has been added to ResearchAndMarkets.com's offering.
  • The North American antibiotics market is expected to reach US$ 18,004.25 million by 2027 from US$ 13,527.79 million in 2019.
  • The antibiotics market is growing primarily due to prevalence of infectious diseases and increasing development of generic drugs in the North America region.
  • On the other hand, fluoroquinolones are expected to register the highest CAGR in the antibiotics market during 2020-2027.

European Antibiotics Market Assessment and Forecast to 2027 with Profiles of GlaxoSmithKline, Sanofi, Novartis, Bayer and Pfizer - ResearchAndMarkets.com

Thursday, July 2, 2020 - 10:28am

The European antibiotics market is expected to reach US$ 15,569.8 million by 2027 from US$ 12,457.7 million in 2019.

Key Points: 
  • The European antibiotics market is expected to reach US$ 15,569.8 million by 2027 from US$ 12,457.7 million in 2019.
  • The antibiotics market is growing primarily due to prevalence of infectious diseases and increasing development of generic drugs in The European region that are boosting the market over the years.
  • Additionally, growing investments to combat antimicrobial resistance and incorporation of novel computing technologies for antibiotics discovery are likely to increase the growth of the antibiotics market in the forecast period.
  • On the other hand, fluoroquinolones are expected to register the highest CAGR in the antibiotics market during 2020-2027.

Crestone, Inc. Secures NIH Funding for Development Through Phase 1 of Novel Antibiotic Candidate CRS0540, A Novel Inhibitor of DNA Replication in Gram-positive Pathogens

Wednesday, July 1, 2020 - 1:00pm

Funding for these studies will be provided entirely by NIHs National Institute of Allergy and Infectious Diseases (NIAID) under Contract No.

Key Points: 
  • Funding for these studies will be provided entirely by NIHs National Institute of Allergy and Infectious Diseases (NIAID) under Contract No.
  • 75N93020C00020 for a total of up to $18.2 million including the base period and subsequent option periods.
  • CRS0540 derives from a series of thiadiazole urea compounds that exhibit potent inhibition of PolC, the catalytic subunit of the replicative DNA polymerase in Gram-positive bacteria.
  • As a novel mechanism of action agent, CRS0540 has shown activity against all clinically relevant antibiotic-resistant Gram-positive pathogens.

Vizient Pharmacy Network Committee Study Published in JAMA Finds Patients with Presumed Penicillin Allergy Given Less Effective, More Harmful Antibiotics

Wednesday, July 1, 2020 - 11:00am

The study, led by researchers at Massachusetts General Hospital, found that physicians unnecessarily prescribe inferior antibiotic alternatives to patients with documented penicillin allergies.

Key Points: 
  • The study, led by researchers at Massachusetts General Hospital, found that physicians unnecessarily prescribe inferior antibiotic alternatives to patients with documented penicillin allergies.
  • The Vizient Pharmacy Network Antimicrobial Stewardship Committee provided the platform for the study as well as facilitated communications and access to data.
  • The dataset included nearly 11,000 inpatients on antibiotics from 106 Vizient member hospitals in the U.S.
  • The research team found that 16% of hospitalized patients with a documented, but unconfirmed, penicillin allergy were twice as likely to be prescribed alternative antibiotics.

DGAP-News: Annual financial statements 2019: 9% sales growth and strongly improved EBITDA; significant milestones and growing interest in pioneering key technologies antibacterial silver coating and resorbable magnesium implants

Tuesday, June 30, 2020 - 10:08pm

In addition, the decision taken in the annual financial statements to no longer capitalize the costs of the two development projects antibacterial silver coating and resorbable magnesium implants will have a full impact on EBIDTA from the 2020 financial year.

Key Points: 
  • In addition, the decision taken in the annual financial statements to no longer capitalize the costs of the two development projects antibacterial silver coating and resorbable magnesium implants will have a full impact on EBIDTA from the 2020 financial year.
  • Against this backdrop, the Management Board expects a significantly lower level of sales and earnings for the financial year 2020.
  • It should be noted, however, that the available forecast data is characterized by a high degree of uncertainty.
  • In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants.

Venatorx Pharmaceuticals Named ‘Best Places to Work’ Third Year in a Row

Tuesday, June 30, 2020 - 6:00pm

Venatorx Pharmaceuticals today announced that it was named one of the 2020 Best Places to Work in the medium-sized company category in the Greater Philadelphia area by the Philadelphia Business Journal.

Key Points: 
  • Venatorx Pharmaceuticals today announced that it was named one of the 2020 Best Places to Work in the medium-sized company category in the Greater Philadelphia area by the Philadelphia Business Journal.
  • Quantum Workplace employee surveys measure each companys culture, from compensation and benefits to trust in senior leadership.
  • Being named a Best Places to Work for the third year in a row comes at a fitting time to acknowledge our teams unwavering commitment to bring lifesaving antibiotics and antiviral medicines to patients around the globe, said Christopher J. Burns, Ph.D. , President and CEO of Venatorx.
  • Founded in 2010, Venatorx has built a world-class in-house R&D organization that has filed over 100 patents spanning multiple research programs.

Polygiene Announces Polygiene ViralOff®+ With Lifetime of Garment Washability

Tuesday, June 30, 2020 - 1:25pm

STOCKHOLM, June 30, 2020 /PRNewswire/ -- In a press conference today, Polygiene announced it is developing a new formula which will provide testable lifetime of garment viral reduction.

Key Points: 
  • STOCKHOLM, June 30, 2020 /PRNewswire/ -- In a press conference today, Polygiene announced it is developing a new formula which will provide testable lifetime of garment viral reduction.
  • Even after 30 washes, the ViralOff+ treated products will reduce more than 99% of the viruses in two hours.
  • "Today, there is some confusion in the market since some claims to washability in fact relies on tests that are not antiviral, but antibacterial", says Daniel Rme, Chief Technology Officer of Polygiene.
  • Subscribe here to get reports, press releases and News:
    For press images and more information, visit ir.polygiene.com or contact:

Polygiene Announces Polygiene ViralOff®+ With Lifetime of Garment Washability

Tuesday, June 30, 2020 - 1:23pm

STOCKHOLM, June 30, 2020 /PRNewswire/ -- In a press conference today, Polygiene announced it is developing a new formula which will provide testable lifetime of garment viral reduction.

Key Points: 
  • STOCKHOLM, June 30, 2020 /PRNewswire/ -- In a press conference today, Polygiene announced it is developing a new formula which will provide testable lifetime of garment viral reduction.
  • Even after 30 washes, the ViralOff+ treated products will reduce more than 99% of the viruses in two hours.
  • "Today, there is some confusion in the market since some claims to washability in fact relies on tests that are not antiviral, but antibacterial", says Daniel Rme, Chief Technology Officer of Polygiene.
  • Subscribe here to get reports, press releases and News:
    For press images and more information, visit ir.polygiene.com or contact:

Outlook into the Hand Wash Global Industry to 2026 - Key Drivers and Restraints - ResearchAndMarkets.com

Monday, June 29, 2020 - 2:29pm

The "Global Hand Wash Market By Distribution Channels, By End User, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hand Wash Market By Distribution Channels, By End User, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Hand wash Market size is expected to reach $11.9 billion by 2026, rising at a market growth of 7.1% CAGR during the forecast period.
  • Liquid hand wash is an antibacterial liquid that contains an active substance used to inhibit, destroy, or render the active bacteria on hands harmless.
  • Liquid hand wash is a multi-million-dollar industry, with continuous market opportunities due to advances in technology and research and development that have resulted in new offerings in the form of organic hand wash and sensitive skin hand wash, among others.